168 related articles for article (PubMed ID: 15247215)
1. Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Sep; 279(37):38395-401. PubMed ID: 15247215
[TBL] [Abstract][Full Text] [Related]
2. Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2002 Aug; 277(31):27585-8. PubMed ID: 12070134
[TBL] [Abstract][Full Text] [Related]
3. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.
Wang Y; Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(46):33247-33251. PubMed ID: 17911111
[TBL] [Abstract][Full Text] [Related]
4. Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR).
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2008 Oct; 283(42):28190-7. PubMed ID: 18708637
[TBL] [Abstract][Full Text] [Related]
5. Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2003 Jan; 278(3):1575-8. PubMed ID: 12421806
[TBL] [Abstract][Full Text] [Related]
6. Locking intracellular helices 2 and 3 together inactivates human P-glycoprotein.
Loo TW; Clarke DM
J Biol Chem; 2014 Jan; 289(1):229-36. PubMed ID: 24275649
[TBL] [Abstract][Full Text] [Related]
7. Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Feb; 279(9):7692-7. PubMed ID: 14670948
[TBL] [Abstract][Full Text] [Related]
8. The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing walker A sequence.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2002 Nov; 277(44):41303-6. PubMed ID: 12226074
[TBL] [Abstract][Full Text] [Related]
9. Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(44):32043-52. PubMed ID: 17848563
[TBL] [Abstract][Full Text] [Related]
10. The ATPase activity of the P-glycoprotein drug pump is highly activated when the N-terminal and central regions of the nucleotide-binding domains are linked closely together.
Loo TW; Bartlett MC; Detty MR; Clarke DM
J Biol Chem; 2012 Aug; 287(32):26806-16. PubMed ID: 22700974
[TBL] [Abstract][Full Text] [Related]
11. Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Apr; 279(18):18232-8. PubMed ID: 14749322
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites.
Ohnuma S; Chufan E; Nandigama K; Jenkins LM; Durell SR; Appella E; Sauna ZE; Ambudkar SV
Biochemistry; 2011 May; 50(18):3724-35. PubMed ID: 21452853
[TBL] [Abstract][Full Text] [Related]
13. Human P-glycoprotein contains a greasy ball-and-socket joint at the second transmission interface.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2013 Jul; 288(28):20326-33. PubMed ID: 23733192
[TBL] [Abstract][Full Text] [Related]
14. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones.
Wang Y; Loo TW; Bartlett MC; Clarke DM
Mol Pharmacol; 2007 Mar; 71(3):751-8. PubMed ID: 17132688
[TBL] [Abstract][Full Text] [Related]
15. Insertion of an arginine residue into the transmembrane segments corrects protein misfolding.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2006 Oct; 281(40):29436-40. PubMed ID: 16926162
[TBL] [Abstract][Full Text] [Related]
16. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2003 Apr; 278(16):13603-6. PubMed ID: 12609990
[TBL] [Abstract][Full Text] [Related]
17. The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator.
Chen EY; Bartlett MC; Loo TW; Clarke DM
J Biol Chem; 2004 Sep; 279(38):39620-7. PubMed ID: 15272010
[TBL] [Abstract][Full Text] [Related]
18. Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane.
Loo TW; Clarke DM
J Biol Chem; 2000 Dec; 275(50):39272-8. PubMed ID: 11013259
[TBL] [Abstract][Full Text] [Related]
19. The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis.
Loo TW; Clarke DM
J Biol Chem; 2000 Feb; 275(8):5253-6. PubMed ID: 10681495
[TBL] [Abstract][Full Text] [Related]
20. Both ATP sites of human P-glycoprotein are essential but not symmetric.
Hrycyna CA; Ramachandra M; Germann UA; Cheng PW; Pastan I; Gottesman MM
Biochemistry; 1999 Oct; 38(42):13887-99. PubMed ID: 10529234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
